ProGRP normal range Pro-gastrin-releasing peptide (ProGRP) is a significant precursor molecule that plays a crucial role in the diagnosis and monitoring of certain cancers, most notably small cell lung cancer (SCLC). As the precursor to gastrin-releasing peptide (GRP), a neuropeptide hormone, ProGRP is frequently produced by SCLC cells. Elevated levels of ProGRP in the blood serum are recognized as a potent biomarker, offering valuable insights into the presence and progression of SCLC and other neuroendocrine tumorsDive into the research topics of 'Pro-gastrin-releasing peptide(ProGRP) in patients with benign and malignant diseases: Comparison with CEA, SCC, CYFRA 21-1 ....
Pro-gastrin-releasing peptide (ProGRP) is a peptide composed of 125 amino acids and serves as the precursor to gastrin-releasing peptide (GRP). GRP itself is a neuropeptide that influences various physiological processes, including the secretion of gastric acid. However, the clinical significance of ProGRP primarily lies in its role as a tumor markerEstablishing next-generation reference intervals for pro .... In the context of SCLC, a highly aggressive form of lung cancer originating from neuroendocrine cells, cancerous cells often overexpress and secrete ProGRP. Consequently, ProGRP levels in the blood can rise considerably, making it a valuable indicator for early detection, treatment response assessment, and recurrence monitoring.
The utility of ProGRP as a biomarker for small cell lung cancer (SCLC) is well-established in numerous scientific studies. Its sensitivity and specificity in identifying SCLC, particularly in comparison to other tumor markers like CEA, SCC, CYFRA 21-1, and NSE, have been extensively investigatedGastrin-releasing peptide is a modulatory neurotransmitter of the .... While histopathology from biopsies remains the gold standard for SCLC diagnosis, ProGRP offers a less invasive and more accessible method for supporting the diagnosis and tracking disease statusHuman Pro-Gastrin-releasing Peptide, proGRP ELISA Kit.
Research indicates that ProGRP levels correlate with tumor extension in SCLCGastrin-releasing peptide is a modulatory neurotransmitter of the .... Studies have reported higher sensitivity rates in extensive disease compared to limited disease, suggesting its utility in assessing the overall burden of SCLC.作者：R MOLINA·2005·被引用次数：180—Pro-gastrin-releasing Peptide(ProGRP) in Patients with Benign and ... We studied the specificity and sensitivity ofprogastrin releasing peptide... Furthermore, monitoring ProGRP levels during treatment can help evaluate therapeutic efficacy. A decrease in ProGRP may indicate a positive response to treatment, while a rise could signal disease progression or relapsePro-gastrin-releasing peptide in patients with benign and ....
While its association with SCLC is most prominent, ProGRP levels have also been observed to be elevated in a variety of other benign and malignant diseases. This broader implication means that while ProGRP is a strong indicator for SCLC, elevated levels alone do not definitively confirm SCLC and should be interpreted within a comprehensive clinical context. Further investigations are often necessary to differentiate between SCLC and other conditions that might lead to increased ProGRP.
The clinical application of ProGRP extends to its use in diagnostic assays, such as enzyme-linked immunosorbent assays (ELISA), which allow for the quantitative detection of ProGRP in serum or plasma.作者：B Nisman·2016·被引用次数：33—Progastrin-releasing peptide(ProGRP) is a potential marker for small-cell lung cancer (SCLC) in serum; however, it may be more stable in ... Establishing accurate reference intervals for ProGRP is crucial for reliable interpretation of test results. Ongoing research continues to explore the full potential of ProGRP, including its role in well-differentiated neuroendocrine tumors and its possible involvement in the physiological functions of certain cancers through ProGRP receptors.
In conclusion, pro-gastrin-releasing peptide stands out as a critical biomarker, particularly for small cell lung cancer. Its ability to be detected in the blood offers a less invasive avenue for diagnosis, monitoring treatment response, and identifying recurrence, thereby contributing significantly to the management of this challenging disease.
Join the newsletter to receive news, updates, new products and freebies in your inbox.